Clinical Trial Update: A Study of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia. [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Mircera in hemodialysis patients with chronic renal anemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• MIRCERA (METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Anemia | Phase 3 | Status: WITHDRAWN